It was found that IDH1 wild-type gliomas, as measured by ALPS index scores, demonstrated significantly lower glymphatic performance than their IDH1 mutant counterparts; no human studies have reported any correlation between changes in glymphatic function and IDH1 mutation status or gene status for any human studies either way [53,63]. Here, IDH1 is linked to central nervous system cancer.